“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart

Article: P36 Can CLL-IPI at time of diagnosis predict who may never need treatment for B-CLL?

€3.03

SKU: product-article-14934 Category: General

Description
Reviews (0)

Description

P36 Can CLL-IPI at time of diagnosis predict who may never need treatment for B-CLL?

Reviews

There are no reviews yet.

Be the first to review “Article: P36 Can CLL-IPI at time of diagnosis predict who may never need treatment for B-CLL?”

You must be logged in to post a review.

Top

Article: P36 Can CLL-IPI at time of diagnosis predict who may never need treatment for B-CLL?

Description

Reviews

Related products

Article: Highlights in melanoma

Article: Highlights in respiratory oncology

Article: Highlights in squamous cell carcinoma of the head and neck

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer